<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992236</url>
  </required_header>
  <id_info>
    <org_study_id>VAS203/I/3/05</org_study_id>
    <nct_id>NCT02992236</nct_id>
  </id_info>
  <brief_title>Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers</brief_title>
  <official_title>Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vasopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winicker Norimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vasopharm GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on
      renal function and perfusion in 16 healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of the effect of i.v. VAS203 on renal function and perfusion in healthy subjects.

      Primary objective:

      Possible adverse effect of VAS203 on the Renal Plasma Flow (RPF) and the Glomerular
      Filtration Rate (GFR) during and after 6 hours of constant-rate iv. infusion of 10 mg/kg
      VAS203.

      Secondary objective:

      To analyse the effects of VAS203 on

        -  filtration fraction

        -  hemodynamics (afferent and efferent resistance, intraglomerular pressure)

        -  markers of kidney injury and renal function

        -  systolic, mean and diastolic brachial blood pressure

        -  Plasma PK of VAS203 and its first metabolite.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal plasma flow</measure>
    <time_frame>2 days</time_frame>
    <description>Renal plasma flow measurement by PAH-Method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>2 days</time_frame>
    <description>by PAH-Method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Filtration fraction</measure>
    <time_frame>2 days</time_frame>
    <description>Ratio glomerular filtration rate / renal plasma flow for p-aminohippuric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean brachial blood pressure</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine concentration</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Function Impairment in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion (6 hours) of Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAS203</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion (6 hours) of VAS203 (10 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAS203</intervention_name>
    <description>Infusion of NO-Synthase inhibitor VAS203</description>
    <arm_group_label>VAS203</arm_group_label>
    <other_name>Ronopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Infusion of saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent in writing available.

          2. Willing and able to comply with all requirements of the study.

          3. Male, 18 and 45 years (inclusive).

          4. Subject has a body weight between 60 kg and 100 kg, extremes included.

          5. BMI 18 to 27 kg/m2.

          6. Non-smoker

          7. Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance &gt; 90
             ml/min

          8. Good general health as judged by the Investigator, as determined by medical history,
             physical examination, vital signs (systolic and diastolic blood pressure and pulse
             rate) and clinical laboratory parameters (clinical chemistry, hematology, and
             urinalysis)

        Exclusion Criteria:

          1. Clinically significant abnormalities in physical examination, vital signs or clinical
             laboratory parameters (according to the Investigator's judgment).

          2. S-GOT or S-GPT levels &gt; 2-times above the upper limit of normal range.

          3. Subject with Cockroft-Gault clearance &lt; 90 ml/min.

          4. Clinically significant history of cardiovascular disease or any known present
             cardiovascular disease.

          5. History of clinically significant neurological, gastrointestinal, renal, hepatic,
             psychological, pulmonary, metabolic, endocrine, hematological, or other major
             disorders.

          6. Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.

          7. Office heart rate at screening after at least 5 minutes outside the range of 50- 99
             beats per minute (inclusive).

          8. Concomitant use of OTC medication within 1 week prior to dosing, except use of
             paracetamol (up to 2 g/day).

          9. Participation in any other clinical study within 30 days prior to inclusion in this -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland E Schmieder, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

